Tempus AI has a data moat no one has replicated: a multimodal, patient-linked genomic, clinical and imaging dataset at scale. It holds over 8 million imaging files, 1.5 million matched clinical and molecular profiles and 4.5 million sequencing samples, which drug companies leaning on AI increasingly need. It is expanding from oncology into cardiology, neuropsychiatry and radiology. Revenue grows 25% and gross margin rose from 32% in 2021 to 64%, though last quarter's profit was a one-time item. … Show more

Tempus AI's diagnostics-to-data-to-AI flywheel makes its roughly 7.2x forward sales interesting, about half Natera's and Guardant's 16x, though both grow faster. Q2 revenue rose 22% to $382.5M, Data Licensing & Modeling grew 36%, and 2026 guidance is about $1.6B of revenue and $65M of adjusted EBITDA. As a ~25% growth diagnostics company, ~7x may be reasonable; if growth reaccelerates toward 30%+, Data + Applications grows much larger and margins expand, the valuation could look very different. … Show more

Tempus AI is a short idea because the stock is being pumped on recent FDA clearances for its EKG-AI tools, while the revenue from them is far off and may never materialize. x.com 

Tempus AI is a data company that happens to sell diagnostics, positioning it for the next re-rate in AI-enabled healthcare and drug discovery. It holds 45M+ de-identified records and 500+ petabytes, growing every time a clinician runs a test. Diagnostics funds the moat, and the data business is the moat, with 41% growth and 73% margins, a layer nobody can rebuild from scratch. x.com 

Tempus AI is still undervalued because its data business alone may be worth a large share of the company. Data and Applications revenue of about $400 million in FY26, growing at management's roughly 30% long-term rate, reaches about $676 million by FY28; at a conservative 12-14x sales that is $8.1-9.5 billion. That leaves the diagnostics business, with about $1.2 billion of revenue, valued at only about $4.5 billion. x.com 

Tempus AI is a second- or third-tier genomic lab whose AI story is marketing mumbo jumbo, and its management team are promoters. x.com 

Tempus AI's Moderna and Merck collaboration puts its oncology data and algorithms to work on cancer vaccines and immuno-oncology drugs, supporting the commercial value of its pharma data platform. The multiyear agreement adds to its licensing case; Q2 revenue rose more than 21.6% to $382 million, and the EPS loss of $0.04 beat the expected $0.20 loss. Sustained profitability remains prospective. Tempus AI could reach $145. x.com 

The new licenses strengthen Tempus AI's long-term $50-100B bull case by monetizing its clinical data in neurology as well as oncology. Per Tempus, Pathos agreed to pay $55M over five years to license a neurology dataset Tempus plans to build from hundreds of thousands of patient records. Tempus also says Bristol Myers Squibb expanded oncology data licensing through 2031 and will gain access to Lens. x.com  x.com  x.com 

Tempus AI's 2025 growth was less impressive than it looks: only half was organic, with the other half coming from the Ambry acquisition. x.com 

Tempus AI has a fresh catalyst and a technical setup that could restart momentum. ARPA-H awarded up to $9.5M to build an autonomous clinical AI agent for heart failure, adding to an FDA clearance for an AI cardiovascular product, the Personalis deal and an AstraZeneca oncology foundation model. Q2 revenue rose 22%, oncology volume 31%, MRD tests reached 9,000, 2026 guidance rose to $1.6B and adjusted EBITDA turned positive. Price found support at the anchored VWAP from the lows. x.com  x.com